Develops enzyme replacement therapies for Mucopolysaccharidosis Type IIIB.
Dec 2025Revenue $0.00/yrExpenses $36.5M/yr
No trendCash runway ≈ 2.3 years from Jun 2026
Figures by year
When will Spruce Biosciences be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $0.00 and expenses $36.5M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $36.5M | −$36.5M |
| Dec 2024 | $4.91M | $61.1M | −$56.2M |
| Dec 2023 | $10.1M | $62.1M | −$52.0M |
| Dec 2022 | $0.00 | $47.3M | −$47.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.